BMT CTN 2203

A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation

Arms / Cohorts

Experimental:Dose Finding Run-In Group 1: Tac/MTX/Ruxolitnib Dose 1

Accepting patients

Experimental:Dose Finding Run-In Group 2: Tac/MTX/Ruxolitnib Dose 2

Accepting patients

Experimental:Main Study Group A: Tac/MTX/Ruxolitnib

Accepting patients

Active Comparator:Main Study Group B: PTCy/Tac/MMF

Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.